- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01110941
Feasibility Study of SOL (S-1,Oral Leucovorin,and Oxaliplatin) for Colorectal Cancer in China (SCI-101)
May 17, 2015 updated by: Shen Lin
A Multicenter Feasibility Study With S-1, Oxaliplatin and Oral Leucovorin (SOL) for the Patients With Untreated Metastatic Colorectal Cancer
S-1 is an oral fluoropyrimidine with demonstrated efficacy on gastric cancer and colorectal cancer.
The new regimen with Oxaliplatin and leucovorin is expected to achieve more encouraging efficacy on colorectal cancer.
This study is to explore the feasibility of the SOL regimen on efficacy and tolerability on Chinese colorectal cancer patients.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
- Endpoints:
- Primary endpoints: adverse drug reaction
Secondary endpoints:
- Overall Response Rate:ORR
- Progress Free Survival: PFS
- Time to Treatment Failure:TTF
Study Type
Interventional
Enrollment (Actual)
20
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100036
- Beijing Cancer Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
Advanced unresectable or recurrent colorectal cancer patients which meet the following criteria:
- Willing to sign ICF
- Could orally take investigational product
- Pathology diagnosis is adenocarcinoma
- Above 20 years
- No previous treatment(including: radiotherapy,chemotherapy and immunotherapy)
- For recurrent cases, if the patient had received adjuvant chemotherapy that didn't include S-1 and L-OHP in 180 days ago, he/she could be enrolled in
- With target lesions with diameter which is longer than 1cm in spiral CT or MRI examination within 30 days
Lab test within 15 days meet following criteria
- Hemoglobin higher than 9.0g/dL
- Leukocyte higher than 12,000/mm3
- Neutrophil higher than 2,000/mm3
- PLT higher than 10.0 104/mm3
- Bilirubin lower than 1.5 times of upper limit of normal range
- AST,ALT,ALP lower than 2.5 times of upper limit of normal range
- Creatinine lower than upper limit of normal range
When patient has liver metastasis or bone metastasis, the value of AST,ALT,ALP could be within 5 times of upper limit of normal range
- ECOG 0 or 1
- Expected survival time more than 90 days
Exclusion Criteria:
- The patient who meet the following criteria should be excluded from this trial
- Patients who have severe drug allergic history(including: platinum related drugs,5-FU,FT,LV,5-HT3 receptor antagonist)
- Attended other clinical trial within 4 weeks
- Received transfusion of blood,related products or G-CSF within 15 days
- Received surgery within 4 weeks and the effect hadn't vanished
- Have diarrhea
- Have complication of active infection(infection caused fever higher than 38℃)
- Have complication of poor controlled hypercalcemia,hypertension,diabetes
- Have complication of severe ECG abnormal or other heart disease which will affect clinical treatment(including: cardiac dysfunction,myocardial infarction,angina)
- Have complication of severe pulmonary disease(including:interstitial pneumonia,pulmonary fibrosis,severe emphysema)
- Have complication of psychiatric disorder which will affect clinical treatment or have history of CNS disease
- Have complication of active gastrointestinal bleeding
- Have pleural effusion,ascites or pericardial effusion that need drainage
- Have complication of multiple bone metastasis
- Have severe complication(including:ileus,renal insufficiency,hepatic insufficiency,cerebrovascular disturbance)
- Have brain metastasis or suspicious brain metastasis
- Have active multiple primary cancer
- Female patients who are in pregnancy or lactation and patients who are not willing to take contraception measures
- Investigator judge not eligible to this trial
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SOL
single arm
|
S-1(20mg、25mg), capsule, 40~60mg, Bid,p.o., day1~7; LV (25 mg), tablet, 25mg,Bid,p.o., day1~7; L-OHP (50 mg),injection 85mg/m2, day1.
repeated at every 2 weeks cycle till disease progression.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of Participants with Adverse Events as a Measure of Safety and Tolerability
Time Frame: from first administration till 28 days after last dosage
|
from first administration till 28 days after last dosage
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Tumor response according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria, and follow up till disease progression or withdrawal from study due to intolerable adverse events (AE)
Time Frame: every 6 weeks
|
every 6 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2009
Primary Completion (Actual)
March 1, 2010
Study Completion (Actual)
October 1, 2010
Study Registration Dates
First Submitted
April 21, 2010
First Submitted That Met QC Criteria
April 26, 2010
First Posted (Estimate)
April 27, 2010
Study Record Updates
Last Update Posted (Estimate)
May 19, 2015
Last Update Submitted That Met QC Criteria
May 17, 2015
Last Verified
May 1, 2015
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Colorectal Neoplasms
- Physiological Effects of Drugs
- Antineoplastic Agents
- Protective Agents
- Micronutrients
- Vitamins
- Antidotes
- Vitamin B Complex
- Oxaliplatin
- Leucovorin
Other Study ID Numbers
- SOL feasibility study
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Colorectal Cancer
-
University of California, San FranciscoCompletedStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedRectal Cancer | Colon Cancer | Cancer Survivor | Colorectal Adenocarcinoma | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage... and other conditionsUnited States
-
M.D. Anderson Cancer CenterRecruitingColorectal Adenocarcinoma | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...United States Department of DefenseActive, not recruitingColorectal Adenoma | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage 0 Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage IIA Colorectal... and other conditionsUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedCancer Survivor | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage IIA Colorectal Cancer AJCC v8 | Stage IIB Colorectal... and other conditionsUnited States
-
City of Hope Medical CenterRecruitingColorectal Neoplasms | Colorectal Cancer | Colorectal Adenocarcinoma | Colorectal Cancer Stage II | Colorectal Cancer Stage III | Colorectal Cancer Stage IV | Colorectal Neoplasms Malignant | Colorectal Cancer Stage IUnited States, Japan, Italy, Spain
-
University of Roma La SapienzaCompletedColorectal Cancer Stage II | Colorectal Cancer Stage III | Colorectal Cancer Stage IV | Colorectal Cancer Stage 0 | Colorectal Cancer Stage IItaly
-
Emory UniversityBristol-Myers Squibb; National Cancer Institute (NCI); National Institutes of...Active, not recruitingColorectal Cancer Metastatic | Colorectal Adenocarcinoma | Stage IV Colorectal Cancer | Stage IVA Colorectal Cancer | Stage IVB Colorectal Cancer | Refractory Colorectal Carcinoma | Metastatic Microsatellite Stable Colorectal Carcinoma | Stage IVC Colorectal CancerUnited States
Clinical Trials on S-1, leucovorin, oxaliplatin
-
Lin ChenUnknownGastric AdenocarcinomaChina
-
Sun Yat-sen UniversityUnknown
-
Peking University Cancer Hospital & InstituteRecruiting
-
Jilin Provincial Tumor HospitalUnknown
-
Fudan UniversityTerminated
-
Sixth Affiliated Hospital, Sun Yat-sen UniversitySun Yat-sen UniversityRecruitingChemotherapy Effect | Locally Advanced Gastroesophageal Junction AdenocarcinomaChina
-
Peking UniversityTaiho Pharmaceutical Co., Ltd.UnknownPancreatic Cancer | Biliary Tract Cancer | Periampullary AdenocarcinomaChina
-
National Cheng-Kung University HospitalChina Medical University Hospital; Taipei Veterans General Hospital, Taiwan; Kaohsiung... and other collaboratorsRecruitingGastric Cancer | Gastric Adenocarcinoma | Toxicity Due to Chemotherapy | Effects of ChemotherapyTaiwan
-
Chinese PLA General HospitalUnknown
-
Chinese PLA General HospitalCure&Sure Biotech Co., LTDUnknownGastric CarcinomaChina